16 november 2020: Aanvullend op onderstaande informatie klik op de titel van deze studie: Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care

En op deze titel: Effect of the botanical formula LCS101 on the anti-cancer effects of radiation therapy

De natuurapotheek kan LCS101 leveren via een goed gekwalificeerd complementair werkende arts. Ook als drankje.

14 april 2018: Lees ook dit artikel en klik op de volgende link: 

https://kanker-actueel.nl/tcm-traditionele-chinese-medicijnen-kruiden-gebruik-naast-chemo-geeft-12-procent-minder-doden-aan-gevorderde-uitgezaaide-borstkanker-over-10-jaar-geregistreerd.html

22 juli 2011: Bron: The oncologist 

Wanneer vrouwen met beginnende borstkanker die chemo krijgen (taxol, taxotere) daarbij oraal een capsule nemen met daarin een mix van Chinese kruiden, dan blijken die vrouwen veel minder last te hebben van de "normale" bijwerkingen als anemia - verminderde rode bloedlichaampjes, verminderde witte bloedlichaampjes (leukopenie en neutropenie) in vergelijking met de groep vrouwen die een placebo kregen. De verschillen waren statisch signicant beter voor de Chinese kruidenmix. anemia (p < .01) en leukopenia (p < .03) vergeleken graad 0–1 met graad 2–4, neutropenia (p < .04) vergeleken graad 0–2 met graad 3–4. Deze studie werd gepubliceerd in The Oncologist en als u hier klikt kunt u het volledige studie rapport inzien tegen betaling. Bij de natuurapotheek in Pijnacker kunt u uitstekende informatie krijgen over beschikbare Chinese kruiden in Nederland. Zij zijn gespecialiseerd in Chinese kruiden als medicijn. 

. 2018 Dec; 17(4): 1020–1026.
Published online 2018 Oct 10. doi: 10.1177/1534735418801528
PMCID: PMC6247551
PMID: 30303021

Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care

Yair Maimon, PhD,1 Noah Samuels, MD,1 Zoya Cohen, PhD,1 Raanan Berger, MD, PhD,1 and David S. Rosenthal, MD2
Author information Article notes Copyright and License information Disclaimer

Abstract

Background and Purpose: LCS101 is a botanical formula extracted from 14 botanical components. While conventional oncology focuses on targeted medicine, research on LCS101 adopts a multi-targeted approach, examining its preclinical (in vitro, in vivo, and ex vivo) and clinical (randomized controlled trial, pragmatic) effects. This includes examining the formula’s impact on the immune system, selective anticancer effects, and improved chemotherapy-related symptoms and quality of life. Effects on the Immune System: In murine splenic cell cultures, LCS101 significantly increased T-cell proliferation and macrophage tumor necrosis factor-α production. Blood samples from healthy volunteers exposed to LCS101 showed a dose-dependent increase in natural killer cell activity; and a randomized controlled trial showed significantly lower rates of leucopenia/neutropenia and anemia in patients with breast cancer undergoing chemotherapy. Selective Anticancer Effects: In vitro LCS101 demonstrated selective growth inhibition (on XTT viability assay) in human breast and prostate cancer cell lines, without any harmful effects on normal human epithelial cells. The anticancer effects were attributed to reactive oxygen species activity. Cytotoxic effects of doxorubicin and 5-fluorouracil on breast cancer cell lines were significantly increased following exposure to LCS101, with a protective effect in normal cells. Symptom Relief and Quality of Life:

En:

Effect of the botanical formula LCS101 on the anti-cancer effects of radiation therapy

Journal of Cancer Research and Clinical Oncology volume 145, pages609–613(2019

Abstract

Background and purpose

The botanical formula LCS101 has been shown in clinical research to reduce chemotherapy-induced toxicities. In pre-clinical research, the formula demonstrated selective anti-cancer effects, in part as a result of radical oxygen species (ROS) activity of the botanical components. The present study examined the interaction between LCS101 and radiation therapy on cancer cell lines.

Methods

Incremental doses of LCS101 were added to breast adenocarcinoma (MCF7), prostate (DU145), transitional cell bladder carcinoma (T24), pancreatic epithelioid carcinoma (PANC-1), and osteosarcoma (U20S) cell lines 4 h after single-dose irradiation (range 0.5–4 Gy). Cell viability was tested using sulforhodamine B (SRB) assay after 1 week, with ROS activity examined using 1 mM of the ROS scavenger sodium pyruvate (ROS scavenger), testing cell viability with an SRB assay.

Results

The addition of LCS101 to MCF7 (breast) and DU-145 (prostate) cancer cell lines resulted in a dose-dependent increase in the antiproliferative effects of radiation treatment. The addition of pyruvate inhibited radiation-induced cell death in all of the cell lines treated with LCS101.

Conclusions

The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.

En:

The addition of LCS101 to anthracycline- and taxane-based chemotherapy is safe and well tolerated, and may significantly prevent some chemotherapy-induced hematological toxicities in early breast cancer patients.

A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer

  1. Neora Yaal-Hahoshena,
  2. Yair Maimonb,e,
  3. Nava Siegelmann-Danielid,
  4. Shahar Lev-Arib,
  5. Ilan G. Rona,
  6. Fani Sperberc,
  7. Noah Samuelsf,
  8. Jacob Shohamg and
  9. Ofer Merimskya

+ Author Affiliations

  1. aDepartment of Oncology, Tel Aviv Sourasky Medical Center affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
  2. bUnit of Complementary Medicine and
  3. cBreast Imaging Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;
  4. dMaccabi Healthcare Services, Tel Aviv, Israel;
  5. eRefuot Integrative Medical Center, Tel Aviv, Israel;
  6. fCenter for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel;
  7. gFaculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
  1. Correspondence: Yair Maimon, Ph.D., Refuot Integrative Medical Center, 18 Feinstein Street, Tel Aviv 69123, Israel. Telephone: 972-3-744–0888; Fax: 972-3-677-7768; e-mail: yair@tcm.org.il
  • Received April 28, 2011.
  • Accepted May 19, 2011.

  • Disclosures: Neora Yaal-Hahoshen: None; Yair Maimon: Ownership interest: Lifebiotic Ltd.; Nava Siegelmann-Danieli: None; Shahar Lev-Ari: None; Ilan Ron: None; Fani Sperber: None; Noah Samuels: None; Jacob Shoham: None; Ofer Merimsky: None.

    The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Abstract

Abstract Background. This prospective, controlled study evaluated the safety, tolerability, and efficacy of the mixture of botanical compounds known as LCS101 in preventing chemotherapy-induced hematological toxicity in breast cancer patients.

Methods. Female patients diagnosed with localized breast cancer were randomly allocated to receive treatment with either LCS101 or placebo capsules, in addition to conventional chemotherapy. The study intervention was initiated 2 weeks prior to the initiation of chemotherapy and continued until chemotherapy was completed, with participants receiving 2 g of LCS101 capsules thrice daily. Subjects were assessed for the development of hematological and nonhematological toxicities, as well as the tolerability and safety of the study intervention.

Results. Sixty-five breast cancer patients were recruited, with 34 allocated to LCS101 and 31 allocated to placebo treatment. Patients in the treatment group developed significantly less severe (grades 2–4) anemia (p < .01) and leukopenia (p < .03) when comparing grades 0–1 with grades 2–4, with significantly less neutropenia (p < .04) when comparing grades 0–2 with grades 3–4. This effect was more significant among patients undergoing a dose-dense regimen. No statistically significant effect was found with respect to nonhematological toxicities, and side effect rates were not significantly different between the groups, with no severe or life-threatening events observed in either group.

Conclusion. The addition of LCS101 to anthracycline- and taxane-based chemotherapy is safe and well tolerated, and may significantly prevent some chemotherapy-induced hematological toxicities in early breast cancer patients. These results should encourage further larger and more extensive clinical trials.

referenties

References

1. Vapiwala N, Mick R, Hampshire MK, Metz JM, DeNittis AS. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J. 2006;12:467-474. [PubMed] []
2. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer. 2005;13:806-811. [PubMed] []
3. Roberts CS, Baker F, Hann D, et al. Patient-physician communication regarding use of complementary therapies during cancer treatment. J Psychosoc Oncol. 2005;23:35-60. [PubMed] []
4. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delblanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252. [PubMed] []
5. Panahi Y, Saadat A, Sahebkar A, Hashemian F, Taghikhani M, Abolhasani E. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr Cancer Ther. 2012;11:204-211. [PubMed] []
6. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105:1230-1238. [PMC free article] [PubMed] []
7. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489-2503. [PubMed] []
8. Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R. Effect of the St. John’s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res. 2005;11(19 pt 1):6972-6979. [PubMed] []
9. Etheridge AS, Kroll DJ, Mathews JM. Inhibition of paclitaxel metabolism in vitro in human hepatocytes by Ginkgo biloba preparations. J Diet Suppl. 2009;6:104-110. [PubMed] []
10. McLay JS, Stewart D, George J, Rore C, Heys SD. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol. 2012;68:811-819. [PubMed] []
11. Richardson MA, Mâsse LC, Nanny K, Sanders C. Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer. 2004;12:797-804. [PubMed] []
12. Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012;140:614-623. [PubMed] []
13. McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24:419-430. [PubMed] []
14. Cassileth BR, Rizvi N, Deng G, et al. Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2009;65:67-71. [PMC free article] [PubMed] []
15. Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Resp J. 2000;15:1087-1093. [PubMed] []
16. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000;88:2686-2692. [PubMed] []
17. Benítez-Bribiesca L, Wong A, Utrera D, Castellanos E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem. 2001;49:1061-1062. [PubMed] []
18. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10:309-313. [PubMed] []
19. Nakakubo Y, Miyamoto M, Cho Y, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer. 2003;89:1736-1742. [PMC free article] [PubMed] []
20. Oshikiri T, Miyamoto M, Shichinohe T, et al. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol. 2003;84:224-228. [PubMed] []
21. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94:1003-1009. [PubMed] []
22. Lee SK, Gasser S. The role of natural killer cells in cancer therapy. Front Biosci (Elite Ed). 2010;2:380-391. [PubMed] []
23. Rachmut IH, Samuels N, Melnick SJ, et al. Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. Onco Targets Ther. 2013;6:437-445. [PMC free article] [PubMed] []
24. Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, et al. A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist. 2011;16:1197-1202. [PMC free article] [PubMed] []
25. Cohen Z, Maimon Y, Yoeli-Lerner M, Yang P, Samuels N, Berger R. Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: implications for cancer treatment. Int J Oncol. 2015;46:308-316. [PubMed] []
26. Maimon Y, Karaush V, Yaal-Hahoshen N, et al. Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J Int Med Res. 2010;38:2033-2039. [PubMed] []
27. Cohen Z, Maimon Y, Samuels N, Berger R. Role of reactive oxygen species in the anticancer activity of botanicals: comparing sensitivity profiles. Oncol Lett. 2017;13:2642-2648. [PMC free article] [PubMed] []
28. Samuels N, Maimon Y, Zisk-Rony RY. Effect of the botanical compound LCS101 on chemotherapy-induced symptoms in patients with breast cancer: a case series report. Integr Med Insights. 2013;8:1-8. [PMC free article] [PubMed] []
29. Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH. Letter to the editor regarding “A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer” by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202). Oncologist. 2012;17:740-741. [PMC free article] [PubMed] []
30. Farrell MP, Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2003;2:253-256. [PubMed] []
31. Kummar S, Copur MS, Rose M, et al. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011;10:85-96. [PubMed] []
Articles from Integrative Cancer Therapies are provided here courtesy of SAGE Publications

References

  1. Bairati I, Meyer F, Gelinas M et al (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23(24):5805–5813

    Article CAS PubMed Google Scholar 

  2. Ben-Arye E, Mahajna J, Aly R, Ali-Shtayeh MS, Bentur Y, Lev E, Deng G, Samuels N (2016) Exploring an herbal “wonder cure” for cancer: a multidisciplinary approach. J Cancer Res Clin Oncol 142:1499–1508

    Article PubMed PubMed Central Google Scholar 

  3. Cohen Z, Maimon Y, Yoeli-Lerner M, Yang P, Samuels N, Berger R (2015) Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: implications for cancer treatment. Int J Oncol 46(1):308–316

    Article CAS PubMed Google Scholar 

  4. Cohen Z, Maimon Y, Samuels N, Berger R (2017) Role of reactive oxygen species in the anticancer activity of botanicals: comparing sensitivity profiles. Oncol Lett 13(4):2642–2648

    Article CAS PubMed PubMed Central Google Scholar 

  5. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delblanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252

    Article CAS PubMed Google Scholar 

  6. Hall E (2000) Repair of radiation damage and the dose-rate effect. In: John J-R, sutton P, Marino D (eds) Radiobiology for the radiologist, 5th edn. Lippincott Williams and Wilkins, Philadelphia, 67–90

    Google Scholar 

  7. Kataoka T (2013) Study of antioxidative effects and anti-inflammatory effects in mice due to low-dose X-irradiation or radon inhalation. J Radiat Res 54(4):587–596

    Article CAS PubMed PubMed Central Google Scholar 

  8. Mathijssen RHJ, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 94:1247–1249

    Article CAS PubMed Google Scholar 

  9. Moertel CG, Fleming TR, Rubin J et al (1982) A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306:201–206

    Article CAS PubMed Google Scholar 

  10. Mooiman KD, Goey AK, Meijerman I, Beijnen JH, Schellens JH (2012) Letter to the editor regarding “A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer” by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197–1202). Oncologist 17(5):740–741 (author reply 742–3)

    Article PubMed PubMed Central Google Scholar 

  11. National Cancer Institute: Antioxidants and Cancer Prevention (2018) https://www.cancer.gov/about-cancer/causes-prevention/risk/diet/antioxidants-fact-sheet. Accessed Aug 2018

  12. Padayatty SJ, Sun H, Wang Y et al (2004) Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140(7):533–537

    Article CAS PubMed Google Scholar 

  13. Pauwels B, Korst AE, de Pooter CM et al (2003) Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 51(3):221-226

    CAS PubMed Google Scholar 

  14. Prasad KN, Kumar R (1996) Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture. Nutr Cancer 26(1):11–19

    Article CAS PubMed Google Scholar 

  15. Prasad KN, Cole WC, Kumar B, Prasad KC (2001) Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 20(5 suppl):450S–463S (discussion 473S–475S)

    Article CAS PubMed Google Scholar 

  16. Rachmut IH, Samuels N, Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J (2013) Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment. Onco Targets Ther 24:6:437–445

    Google Scholar 

  17. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN (2006) Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J Control Release 20(113):189–207

    Article CAS Google Scholar 

  18. Sakamoto K, Sakka M (1973) Reduced effect of irradiation on normal and malignant cells irradiated in vivo in mice pretreated with vitamin E. Br J Radiol 46(547):538–540

    Article CAS PubMed Google Scholar 

  19. Samuels N, Maimon Y, Zisk-Rony RY (2013) Effect of the botanical compound LCS101 on chemotherapy-induced symptoms in patients with breast cancer: a case series report. Integr Med Insights 8:1–8

    Article PubMed PubMed Central Google Scholar 

  20. Witenberg B, Kletter Y, Kalir HH, et al (1999) Ascorbic acid inhibits apoptosis induced by X irradiation in HL60 myeloid leukemia cells. Radiat Res 152(5):468–478

    Article CAS PubMed Google Scholar 

  21. Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O (2011) A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist 16(9):1197–1202

    Article CAS PubMed PubMed Central Google Scholar 

taxotere, taxol, chemo, borstkanker, Chinese kruiden, TCM, LCS101


Plaats een reactie ...

Reageer op "Borstkanker: Chinese kruidenmix - LCS101 - vermindert significant bijwerkingen van chemo bij vrouwen met borstkanker die chemo krijgen."


Gerelateerde artikelen
 

Gerelateerde artikelen

Zhengyuan-capsule gecombineerd >> Borstkanker: Chinese kruidenmix >> Borstkanker: Shenqui Fuzheng >> Borstkanker: Injecties met >> Borstkanker: TCM - Traditionele >>